Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients
NCT ID: NCT00044538
Last Updated: 2009-06-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
102 participants
INTERVENTIONAL
2001-12-31
2004-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer
NCT00054314
BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)
NCT00533585
BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)
NCT00101413
Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
NCT01069328
A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
NCT00558636
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
BAY59-8862 (Cytotoxic Taxane)
Intravenous dose over 60 minutes every 3 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BAY59-8862 (Cytotoxic Taxane)
Intravenous dose over 60 minutes every 3 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must have received at least 3 weeks of continuous therapy with Taxane - patient must subsequently develop progressive disease either during treatment or within 6 months after treatment
* Life expectancy of at least 12 weeks
* Adequate bone marrow, liver and kidney function
Exclusion Criteria
* excluded therapies and medications, previous and concomitant such as: anticancer chemotherapy or immunotherapy during the study or within 4 weeks prior to study entry; more than two prior anticancer chemotherapy regimens; radiotherapy during study or within 4 weeks prior to study entry; bone marrow transplant.
* others: pregnant or breast-feeding patients; both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial; substance abuse, medical, psychological or social conditions that may interfere with the patient's participation.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bayer HealthCare AG
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tucson, Arizona, United States
Waterbury, Connecticut, United States
Louisville, Kentucky, United States
Metairie, Louisiana, United States
Buffalo, New York, United States
Columbus, Ohio, United States
Nashville, Tennessee, United States
Edmonton, Alberta, Canada
Hamilton, Ontario, Canada
Thunder Bay, Ontario, Canada
Montreal, Quebec, Canada
Québec, Quebec, Canada
Gauting, Bavaria, Germany
Berlin, State of Berlin, Germany
Kfar Saba, , Israel
Tel Aviv, , Israel
Tel Litwinsky, , Israel
Modena, , Italy
Parma, , Italy
Pisa, , Italy
Torino, , Italy
Udine, , Italy
Elche, Alicante, Spain
Barcelona, Barcelona, Spain
Barakaldo, Bizkaia, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10653
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.